Idaho Senate panel holds extensive informational hearing on bill to pause gene-therapy products for infectious diseases

The Idaho Senate Health and Welfare Committee convened an informational hearing on Senate Bill 10 36 — titled the Doug Cameron Act — that would impose a moratorium on the administration of gene‑therapy products for infectious‑disease indications.

The measure’s sponsor, Sen. Brandon Shippey, told the committee the bill was prompted by a constituent’s injury and said the moratorium is intended to pause use of what the bill describes as gene‑therapy products until more study and oversight are completed. "This was not a brainchild of myself," Shippey said, noting the bill’s namesake and the constituent-led push behind it.

Supporters who testified described a range of adverse events they attribute to COVID‑19 mRNA and related products and urged a pause. Doug Cameron, who identified himself as the bill’s namesake, told the committee he was paralyzed after receiving a Johnson & Johnson COVID vaccine and said his combined medical bills and out‑of‑pocket expenses have exceeded $2,000,000. "The pause is necessary, and Idaho can be and should be leading the charge," Cameron said.

Opponents, including practicing clinicians and researchers, said the bill would remove a tool used in pandemic response and impede development of medical countermeasures. Emergency physician Jessica Evans Wall, who testified against the measure, said vaccines reduced deaths during the pandemic and warned that a moratorium could harm preparedness for future novel pathogens.

Why it matters: testimony split sharply between personal injury accounts and scientific critiques. Proponents argued federal regulators failed to protect the public and cited VAERS reports, v‑safe data and concerns about manufacturing, DNA contamination and long‑term safety signals. Opponents and several clinicians urged caution before enacting a broad moratorium that could affect vaccine research, clinical care and emergency response.

Key testimony and themes - Safety concerns and personal injury: Doug Cameron described a severe, prolonged disability he attributes to a Johnson & Johnson shot. Several other witnesses described myocarditis, neurological injury or deaths they said followed vaccination. - Scientific and regulatory arguments: Several witnesses with scientific backgrounds urged market withdrawal or a pause. Dr. Peter McCullough (practicing internist and cardiologist in Dallas) and Dr. Christina Parks (researcher discussing gene‑therapy risk and the need for extended surveillance) urged halting gene‑therapy products pending longer safety follow‑up. Witnesses cited the PREP Act, VAERS, and v‑safe as parts of the public record they say show safety signals. - Opposition from clinicians and researchers: Dr. Skye Blue (infectious diseases clinician) and other health professionals said mRNA vaccines saved lives during the pandemic and argued the bill would limit options in future outbreaks and harm patients who benefit from vaccination. - Research and laboratory practice concerns: Dr. Haley Bridgewater (vaccine researcher) and other witnesses described laboratory uses of plasmids and ex vivo cell methods that could be affected if the bill’s language is applied to research activities.

What the committee did: The hearing was informational only. Committee members were told the sponsor expects to revise the proposal and that no final vote would be taken at this meeting. Senator Shippey indicated he expects changes and sought feedback from experts and members.

Context and next steps: Witnesses on both sides asked for additional review and data. Proponents pressed for a formal pause and full manufacturer liability; opponents pressed for narrow, evidence‑based policymaking that preserves public health tools. The sponsor said he would consider amendments before the bill advances.

Speakers quoted in this article came from the meeting record and testimony provided to the committee.